Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.

IF 5.4 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Communications medicine Pub Date : 2025-01-16 DOI:10.1038/s43856-024-00713-6

Farwa Ali, Jeremy A Syrjanen, Dan J Figdore, Walter K Kremers, Michelle M Mielke, Clifford R Jack, David S Knopman, Prashanthi Vemuri, Jonathan Graff-Radford, B Gwen Windham, Leland R Barnard, Ronald C Petersen, Alicia Algeciras-Schimnich

{"title":"Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.","authors":"Farwa Ali, Jeremy A Syrjanen, Dan J Figdore, Walter K Kremers, Michelle M Mielke, Clifford R Jack, David S Knopman, Prashanthi Vemuri, Jonathan Graff-Radford, B Gwen Windham, Leland R Barnard, Ronald C Petersen, Alicia Algeciras-Schimnich","doi":"10.1038/s43856-024-00713-6","DOIUrl":null,"url":null,"abstract":"Background: Declining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer's disease (Aβ 42/40 ratio, P-Tau181).Methods: In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer's Disease pathology are associated with worse gait performance. A sample of 2641 Mayo Clinic Study of Aging participants with measurements of plasma biomarkers and gait parameters was analyzed in this cross-sectional study. Linear regression models using plasma biomarkers as predictors of gait parameters and adjusted for age, sex, BMI, Charlson Comorbidity Index, and cognitive diagnosis were evaluated.Results: In this study multiple statistically significant relationships are observed for GFAP, NfL, and P-Tau181 with gait parameters. Each standard deviation increase in GFAP, NfL, and P-Tau181 is associated with a reduction in velocity of 2.100 (95% CI: -3.004, -1.196; p = 5.4 × 10-6), 4.400 (-5.292, -3.507; p = 9.5 × 10-22), and 2.617 (-3.414, -1.819; p = 1.5 × 10-10) cm/sec, respectively. Overall, NfL has the strongest associations with poor gait performance. Models with age interactions show that the strength of associations between the plasma biomarkers and the gait parameters became stronger with increasing age. There are no specific gait parameters that associate with individual plasma biomarkers.Conclusion: Plasma biomarkers of neurodegeneration and Alzheimer's Disease pathology are not only markers of cognitive decline but also indicate motor decline in the aging population.","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"19"},"PeriodicalIF":5.4000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739691/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s43856-024-00713-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Declining gait performance is seen in aging individuals, due to neural and systemic factors. Plasma biomarkers provide an accessible way to assess evolving brain changes; non-specific neurodegeneration (NfL, GFAP) or evolving Alzheimer's disease (Aβ 42/40 ratio, P-Tau181).

Methods: In a population-based cohort of older adults, we evaluate the hypothesis that plasma biomarkers of neurodegeneration and Alzheimer's Disease pathology are associated with worse gait performance. A sample of 2641 Mayo Clinic Study of Aging participants with measurements of plasma biomarkers and gait parameters was analyzed in this cross-sectional study. Linear regression models using plasma biomarkers as predictors of gait parameters and adjusted for age, sex, BMI, Charlson Comorbidity Index, and cognitive diagnosis were evaluated.

Results: In this study multiple statistically significant relationships are observed for GFAP, NfL, and P-Tau181 with gait parameters. Each standard deviation increase in GFAP, NfL, and P-Tau181 is associated with a reduction in velocity of 2.100 (95% CI: -3.004, -1.196; p = 5.4 × 10^-6), 4.400 (-5.292, -3.507; p = 9.5 × 10^-22), and 2.617 (-3.414, -1.819; p = 1.5 × 10^-10) cm/sec, respectively. Overall, NfL has the strongest associations with poor gait performance. Models with age interactions show that the strength of associations between the plasma biomarkers and the gait parameters became stronger with increasing age. There are no specific gait parameters that associate with individual plasma biomarkers.

Conclusion: Plasma biomarkers of neurodegeneration and Alzheimer's Disease pathology are not only markers of cognitive decline but also indicate motor decline in the aging population.

查看原文本刊更多论文

老年痴呆症病理和神经退行性变的血浆生物标志物与步态表现的关系。

背景：由于神经和全身因素，在老年人中可以看到步态性能下降。血浆生物标志物为评估不断变化的大脑变化提供了一种可行的方法；非特异性神经变性（NfL， GFAP）或发展中的阿尔茨海默病（Aβ 42/40比值，P-Tau181）。方法：在以人群为基础的老年人队列中，我们评估了神经变性和阿尔茨海默病病理的血浆生物标志物与较差的步态表现相关的假设。本横断面研究分析了2641名梅奥诊所老年研究参与者的血浆生物标志物和步态参数测量。使用血浆生物标志物作为步态参数预测因子的线性回归模型，并根据年龄、性别、BMI、Charlson合并症指数和认知诊断进行调整。结果：在本研究中，GFAP、NfL和P-Tau181与步态参数之间存在多个统计学意义上的关系。GFAP、NfL和P-Tau181每增加一个标准差，流速降低2.100 (95% CI: -3.004, -1.196；P = 5.4 × 10-6), 4.400 (-5.292, -3.507；P = 9.5 × 10-22)、2.617 (-3.414,-1.819；P = 1.5 × 10-10) cm/sec。总的来说，NfL与步态表现差有最强的联系。具有年龄相互作用的模型显示，血浆生物标志物与步态参数之间的关联强度随着年龄的增长而增强。没有特定的步态参数与个体血浆生物标志物相关。结论：老年人群神经退行性变和阿尔茨海默病病理的血浆生物标志物不仅是认知能力下降的标志，而且是运动能力下降的标志。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Communications medicine

自引率

0.00%

发文量